Catalyst
Slingshot members are tracking this event:
Ionis Pharma (IONS) to complete Phase 1/2a study of ISIS-DMPKRx in Adults with Myotonic Dystrophy Type 1 by end of 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IONS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 02, 2016
Occurred Source:
https://clinicaltrials.gov/archive/NCT02312011/2016_11_02/changes
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 1/2 Study, Isis-dmpkrx, Myotonic Dystrophy, Muscular Dystrophy, Isis-dmpkrx
